Oculopharyngeal muscular dystrophy as a cause of progression of weakness in antibody positive myasthenia gravis

Björn Oskarsson; Steven P. Ringel

doi:10.1016/j.nmd.2013.01.012

Oculopharyngeal muscular dystrophy as a cause of progression of weakness in antibody positive myasthenia gravis

Björn Oskarsson, Steven P. Ringel

Neurology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Many neuromuscular conditions cause bulbar and limb weakness, and when several conditions coexist they present additional diagnostic challenges. Here we describe a case of a 45-year-old woman with antibody positive myasthenia gravis since age 16, who then develops treatment-resistant weakness due to genetically proven oculopharyngeal muscular dystrophy. We conclude that the development of treatment-resistant weakness in myasthenia gravis should spur further work up for other neuromuscular disorders including oculopharyngeal muscular dystrophy.

Original language	English (US)
Pages (from-to)	316-318
Number of pages	3
Journal	Neuromuscular Disorders
Volume	23
Issue number	4
DOIs	https://doi.org/10.1016/j.nmd.2013.01.012
State	Published - Apr 2013

Keywords

Myasthenia gravis (MG)
Oculopharyngeal muscular dystrophy (OPMD)

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Neurology
Clinical Neurology
Genetics(clinical)

Access to Document

10.1016/j.nmd.2013.01.012

Cite this

@article{d3a1dbcffd6e47ca94acda6d58b50d76,

title = "Oculopharyngeal muscular dystrophy as a cause of progression of weakness in antibody positive myasthenia gravis",

abstract = "Many neuromuscular conditions cause bulbar and limb weakness, and when several conditions coexist they present additional diagnostic challenges. Here we describe a case of a 45-year-old woman with antibody positive myasthenia gravis since age 16, who then develops treatment-resistant weakness due to genetically proven oculopharyngeal muscular dystrophy. We conclude that the development of treatment-resistant weakness in myasthenia gravis should spur further work up for other neuromuscular disorders including oculopharyngeal muscular dystrophy.",

keywords = "Myasthenia gravis (MG), Oculopharyngeal muscular dystrophy (OPMD)",

author = "Bj{\"o}rn Oskarsson and Ringel, {Steven P.}",

note = "Funding Information: The project described was supported by the National Center for Advancing Translational Sciences , National Institutes of Health , through UL1 TR 000002 and KL2 TR 000134 .",

year = "2013",

month = apr,

doi = "10.1016/j.nmd.2013.01.012",

language = "English (US)",

volume = "23",

pages = "316--318",

journal = "Neuromuscular Disorders",

issn = "0960-8966",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Oculopharyngeal muscular dystrophy as a cause of progression of weakness in antibody positive myasthenia gravis

AU - Oskarsson, Björn

AU - Ringel, Steven P.

N1 - Funding Information: The project described was supported by the National Center for Advancing Translational Sciences , National Institutes of Health , through UL1 TR 000002 and KL2 TR 000134 .

PY - 2013/4

Y1 - 2013/4

N2 - Many neuromuscular conditions cause bulbar and limb weakness, and when several conditions coexist they present additional diagnostic challenges. Here we describe a case of a 45-year-old woman with antibody positive myasthenia gravis since age 16, who then develops treatment-resistant weakness due to genetically proven oculopharyngeal muscular dystrophy. We conclude that the development of treatment-resistant weakness in myasthenia gravis should spur further work up for other neuromuscular disorders including oculopharyngeal muscular dystrophy.

AB - Many neuromuscular conditions cause bulbar and limb weakness, and when several conditions coexist they present additional diagnostic challenges. Here we describe a case of a 45-year-old woman with antibody positive myasthenia gravis since age 16, who then develops treatment-resistant weakness due to genetically proven oculopharyngeal muscular dystrophy. We conclude that the development of treatment-resistant weakness in myasthenia gravis should spur further work up for other neuromuscular disorders including oculopharyngeal muscular dystrophy.

KW - Myasthenia gravis (MG)

KW - Oculopharyngeal muscular dystrophy (OPMD)

UR - http://www.scopus.com/inward/record.url?scp=84874999329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874999329&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2013.01.012

DO - 10.1016/j.nmd.2013.01.012

M3 - Article

C2 - 23453859

AN - SCOPUS:84874999329

SN - 0960-8966

VL - 23

SP - 316

EP - 318

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

IS - 4

ER -

Oculopharyngeal muscular dystrophy as a cause of progression of weakness in antibody positive myasthenia gravis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this